231 related articles for article (PubMed ID: 23991948)
1. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer.
Han D; Li SJ; Zhu YT; Liu L; Li MX
Asian Pac J Cancer Prev; 2013; 14(7):4033-9. PubMed ID: 23991948
[TBL] [Abstract][Full Text] [Related]
2. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
Green AS; Chapuis N; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Cell Cycle; 2011 Jul; 10(13):2115-20. PubMed ID: 21572254
[TBL] [Abstract][Full Text] [Related]
3. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells.
Dong LX; Sun LL; Zhang X; Pan L; Lian LJ; Chen Z; Zhong DS
Acta Pharmacol Sin; 2013 Feb; 34(2):314-8. PubMed ID: 23178462
[TBL] [Abstract][Full Text] [Related]
5. Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogic acid.
Li X; Tang X; Su J; Xu G; Zhao L; Qi Q
Biochem Pharmacol; 2019 Nov; 169():113635. PubMed ID: 31513784
[TBL] [Abstract][Full Text] [Related]
6. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
9. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
[TBL] [Abstract][Full Text] [Related]
10. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.
Ekman S; Wynes MW; Hirsch FR
J Thorac Oncol; 2012 Jun; 7(6):947-53. PubMed ID: 22588151
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner.
Meng J; Majidi M; Fang B; Ji L; Bekele BN; Minna JD; Roth JA
PLoS One; 2013; 8(10):e77067. PubMed ID: 24146957
[TBL] [Abstract][Full Text] [Related]
12. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
13. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
14. Targeting LKB1 signaling in cancer.
Korsse SE; Peppelenbosch MP; van Veelen W
Biochim Biophys Acta; 2013 Apr; 1835(2):194-210. PubMed ID: 23287572
[TBL] [Abstract][Full Text] [Related]
15. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Liu JL; Mao Z; Gallick GE; Yung WK
Neuro Oncol; 2011 Feb; 13(2):184-94. PubMed ID: 21123367
[TBL] [Abstract][Full Text] [Related]
16. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
17. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
[TBL] [Abstract][Full Text] [Related]
18. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.
Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ
Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328
[TBL] [Abstract][Full Text] [Related]
19. CO suppresses prostate cancer cell growth by directly targeting LKB1/AMPK/mTOR pathway in vitro and in vivo.
Yan Y; Du C; Li G; Chen L; Yan Y; Chen G; Hu W; Chang L
Urol Oncol; 2018 Jun; 36(6):312.e1-312.e8. PubMed ID: 29566977
[TBL] [Abstract][Full Text] [Related]
20. Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Kang JI; Hong JY; Lee HJ; Bae SY; Jung C; Park HJ; Lee SK
PLoS One; 2015; 10(12):e0144368. PubMed ID: 26656173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
